Equities

Zentalis Pharmaceuticals Inc

ZNTL:NMQ

Zentalis Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.92
  • Today's Change0.21 / 5.66%
  • Shares traded2.23m
  • 1 Year change-61.79%
  • Beta1.8333
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments483437340
Total Receivables, Net3.346.380.00
Total Inventory------
Prepaid expenses9.967.5211
Other current assets, total0.500.660.24
Total current assets497452351
Property, plant & equipment, net425053
Goodwill, net3.743.743.74
Intangibles, net----0
Long term investments02137
Note receivable - long term------
Other long term assets------
Total assets552539455
LIABILITIES
Accounts payable151112
Accrued expenses544531
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.280.380.97
Total current liabilities695744
Total long term debt000
Total debt000
Deferred income tax00.851.62
Minority interest0.110.220.53
Other liabilities, total454844
Total liabilities11410691
SHAREHOLDERS EQUITY
Common stock0.070.060.05
Additional paid-in capital1,3241,031724
Retained earnings (accumulated deficit)(889)(596)(360)
Treasury stock - common------
Unrealized gain (loss)--(1.35)(0.13)
Other equity, total2.19----
Total equity437434364
Total liabilities & shareholders' equity552539455
Total common shares outstanding715945
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.